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The membrane proteins signal peptide peptidase, signal peptide peptidase like and 
presenilin are intramembrane aspartyl proteases located in the endoplasmic reticulum, 
plasma membrane and organelles. These membrane proteins are able to catalyze a 
hydrolytic reaction in a hydrophobic space. The downstream consequences of these 
reactions impact a variety of cellular functions such as cytokine production, inflammatory 
responses, embryogenesis, and immune system regulation. Additionally, the aspartyl 
proteases such as signal peptide peptidase and presenilin, a part of the γ-secretase 
complex, hydrolyze peptides leading to pathogen maturation and Alzheimer’s disease, 
respectively. 
 
Electron crystallography offers the unique aspect of studying membrane proteins in a 
near native state. Determining the structures of Haloarcula morismortui and 
Methanoculleus marisnigri JR1 signal peptide peptidases by electron crystallography 
may provide insight into how a hydrolysis reaction occurs in a hydrophobic environment 
and how the protein determines which transmembrane signal peptides to cleave. 
Additionally, structure determination may help answer questions regarding why human 
presenilin, part of the γ-secretase complex, incorrectly processes amyloid precursor 
protein into amyloid-beta peptides leading to Alzheimer’s disease. Such structural data 
may not only shed light on how amyloid precursor protein is processed but how other 
proteins are processed by signal peptide peptidase leading to immune responses, cell 
signaling, and pathogen maturation. In addition, structure-function data may have an 
 xiv 
impact on pharmaceutical drug designs that targets signal peptide peptidase, signal 
peptide peptidase like, and/or presenilin. 
 
To determine the structure of aspartyl proteases, two archaeal signal peptide peptidases 
were used for two-dimensional crystallization trials to be able to study their structure by 
electron crystallography. Haloarcula morismortui and Methanoculleus marisnigri JR1 
signal peptide peptidases, both human signal peptide peptidase homologues, were 
recombinantly over-expressed and purified. During dialysis trials, various lipid-to-protein 
ratios, sodium chloride concentrations, temperatures, detergents and a variety of other 
variables were tested.  
 
Methanoculleus marisnigri JR1 signal peptide peptidase showed the most promising 
results in terms of crystallinity. Optimizing dialysis conditions, specifically narrowing the 
lipid-to-protein ratio, resulted in two-dimensional crystals. Ordered arrays measuring up 
to 200 nm x 200 nm were observed. These ordered arrays have been shown to be 
reproducible amongst multiple batches of purified Methanoculleus marisnigri JR1 signal 
peptide peptidase. Preliminary projection maps of negatively stained ordered arrays show 
unit cell dimensions of a = 178 Å, b = 160 Å, γ = 92.0 Å and a = 175 Å, b = 167 Å, γ = 
92.0 Å. The monomer measurements are approximately 70 Å by 80 Å. This is the first 









1.1 Membrane Protein Overview 
The human genome is estimated to contain 20-30% membrane proteins (1). They are 
found at the cell surface associated with the cellular membrane, and intracellularly, 
embedded within the lipid bilayers of organelles. Membrane proteins carry out a diverse 
set of cellular functions such as transport, enzymatic activity, signal transduction, 
intracellular junctions, cell-cell recognition and attachment to the cytoskeleton and 
extracellular matrix (2). 
 
Membrane proteins are significant in that approximately 60% of drugs approved by the 
Food and Drug Administration target these types of proteins (3). In a 50 billion dollar 
industry three of the top four drug targets are membrane proteins and consist of the class I 
G-protein coupled receptors, ligand-gated ion channels and voltage-gated ion channels 
(4). Given these statistics, little is known about the overall structure of membrane 
proteins in their native membrane-bound state and the drug interactions that affect them.  
 
There are two types of membrane proteins, those with β-barrels and those with α-helical 
transmembrane domains. β-barrels are composed of 8 to 24 β-sheets that form a pore. 
They are found in the outer membranes of Gram-negative bacteria, chloroplasts and 
mitochondria. They function as porins, transporters, and receptors (5). Membrane 
proteins with α-helical transmembrane domains are composed of one or more α-helices 
extending through the lipid bilayer. An α-helix is composed of a linear sequence of amino 
acids that fold into right-handed helices stabilized by internal hydrogen bonding. This 
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group of membrane proteins is critical in transport, signaling, enzymatic activity and 
attachment to the extracellular matrix (6).   
 
1.2 Electron Crystallography 
Henderson and Unwin solved the first three-dimensional (3D) model of the membrane 
protein bacteriorhodopsin at 7 Å resolution in 1975 utilizing electron crystallography (7). 
Since 1975, the structures of bacteriorhodopsin as well as other membrane proteins have 
been solved at atomic resolution (8). Approximately 0.5% of all of the structures that 
have been deposited into the Protein Data Bank (PDB) are membrane proteins (9). As of 
March 2014, out of 91246 protein entries entered in the PDB, approximately 1% are 
membrane proteins. The PDB currently contains 2,274 membrane protein structures as of 
March 2014; this number is directly related to difficulties in attempting to crystallize 
membrane proteins. In the case of bacteriorhodopsin, this membrane protein naturally 
forms two-dimensional (2D) crystalline arrays in the membrane of Halobacterium 
salinarium (10). From these naturally occurring 2D crystals, Henderson and Unwin were 
able to solve the first 3D structure where α-helices could be ascertained (7). Most other 
membrane proteins require additional steps and considerations for 2D crystallization as 




Figure 1: Overview of electron crystallography. The first step is to overexpress and 
purify a stable membrane protein at high concentrations for dialysis trials. Step 2 is the 
process of setting up 2D crystallization conditions that will lead to formation of 2D 
crystals. Step 3 involves negative staining and evaluating dialysis samples at the 
transmission electron microscope. Steps 1-3 may need to be repeated multiple times 
before ideal conditions are identified. Once ideal conditions are found, samples can be 
prepared for electron cryo-microscopy (cryo-EM) conditions. Step 4, carbon coated grids 
containing samples are plunged into liquid nitrogen and are kept under cryo-EM 
conditions. Step 5 is the process of collecting tilted images of the sample followed by 
image processing (step 6) and evaluation of collected data. Step 7, 2D and 3D data results 
in projection maps and 3D models (11). 
 
The first hurdle is identifying an expression vector that produces adequate amounts of 
stable and properly folded membrane proteins that can be purified (12, 13). The step 
following protein purification is one of the major bottlenecks in electron crystallography 
2D crystallization trials. These trials involve testing and screening many variables that 
may or may not produce ideal 2D crystals (14, 15, 16) Following the determination of the 
appropriate crystallizations parameters, the 2D crystals need to be prepared and imaged 
under electron cryo-microscopy (cryo-EM) conditions (17). The next step is to obtain 
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high resolution images (18). A stable, properly aligned transmission electron microscope 
with a strong coherent beam is essential for accomplishing this step. After collecting the 
high resolution images, image processing is necessary to generate projection maps and 
3D models (19). The final outcome is a structure that may be used to describe protein 
function, protein-protein interactions and/or protein-drug interactions.  
 
1.3 Intramembrane-Cleaving Proteases 
Three families of intramembrane-cleaving proteases (I-CLiPs) have been identified, 
rhomboid, site-2, and GxGD proteases. These specialized enzymes catalyze peptide bond 
cleavage within the hydrophobic environment of the lipid bilayer. The I-CLiPs are 
involved in a range of cellular activities, which include development, organelle shaping, 
metabolism, pathogenicity and degenerative disease (20). 
 
1.4 Aspartyl Proteases 
Signal peptide peptidase (SPP) and homologous SPP-like (SPPL) are GxGD proteases 
characterized by two aspartic acid residues which activate a water molecule to cleave a 
peptide bond (Figure 2). These highly conserved intramembrane proteases have been 
found embedded in the membranes of organelles and the plasma membrane (20).  
 
SPP/SPPL are found in a wide range of plants and organisms and contribute to a diverse 
set of cellular functions (21, 22, 23). SPP/SPPL are predicted to have nine 
transmembrane domains (24). The two catalytic aspartic acid residues characterized by 
YD and GxGD amino acid motifs are located on transmembrane domains 6 and 7, 
respectively. Another conserved motif, the proline-alanine-leucine (PAL) sequence is 
located on the N-terminal portion of transmembrane domain 9 (Figure 3). If proline, 
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alanine or leucine are mutated, SPP and PS catalytic activity is significantly diminished.  
(21, 22, 23, 25, 26, 27, 28) 
 
Located in the ER, SPP cleaves signal peptides from the ER membrane after they have 
been released from nascent polypeptides by signal peptidase (Figure 4) (29). There is 
evidence that suggests that SPP exists in vivo as an active homodimer (30) however in 
vitro investigations utilizing x-ray crystallography and single particle analysis suggest 




Figure 2: Proposed aspartyl protease mechanism. The two aspartate residues act like an 
acid-base mechanism. A water molecule situated between the two aspartate residues is 
activated leading to the nucleophilic oxygen molecule attacking the carbonyl group of the 




Figure 3: SPP topology. SPP contains 9 transmembrane domains with the aspartic acid 
residues located on transmembrane domains 6 and 7 and the PAL sequence on 





Figure 4: SPP cleavage of signal peptides from the ER membrane. Signal peptidases 
cleave the N-terminal signal peptide from the nascent polypeptide translating through the 




SPP is involved in virus maturation, cellular signaling and immune surveillance. The core 
protein of hepatitis C virus is processed by SPP allowing for maturation of the virus (34, 
35, 36). SPP is also required for the maturation of GB virus B core protein (37). SPP may 
be involved in the degradation of misfolded proteins (38, 39). Furthermore, SPP cleaves 
the signal peptide derived from newly synthesized major histocompatibility complex 
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class 1b molecules. This fragment is expressed as the human lymphocyte antigen binding 
epitope (40). Additionally, SPP cleaves the signal peptide of pre-prolactin as well as the 
signal peptide of HIV envelope protein p-gp160. Both peptides bind to calmodulin in 
vitro. Further investigations into the relevance of calmodulin interactions with signal 
peptides remains to be completed (41, 42).  
 
Another intramembrane aspartyl protease, presenilin (PS), also is characterized by nine 
transmembrane domains, which contain the YD, GxGD, and PAL motifs (43). Unlike 
SPP, PS undergoes autoendolysis and requires additional proteins that include nicastrin, 
aneroid pharynx defective 1 and presenilin enhancer 2, to form the fully active 𝛾-
secretase complex. Unlike SPP/SPPL, PS transmembrane domains 6 and 7 are in the 
opposite orientation, enabling processing of type-I anchored membrane proteins (Figure 
5) (21, 24, 44). 
 
Figure 5: PS topology. PS and SPP show similar membrane topology. Presenilin contains 
9 transmembrane domains and has the opposite orientation compared to SPP, allowing 
for processing of type I anchored membrane proteins. The aspartic acid residues are 
located on transmembrane domains 6 and 7 and the PAL sequence is located on 
transmembrane domain 9. PS undergoes post-translational processing between 
transmembrane domains 6 and 7. The autoendolytic activity separates PS into an N-
terminal and C-terminal fragment. Additional proteins are required for PS to function and 
to form the ɣ-secretase complex (32). 
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1.5 Structural Studies of Archaeal Proteases mSPP and MCMJRSPP 
To investigate the structures of aspartyl proteases SPP and PS by electron 
crystallography, two SPP homologues from two different archaeal bacteria were over-
expressed and purified for 2D crystallization trials, Haloarcula morismortui SPP (mSPP) 
and Methanoculleus marisnigri JR1 (MCMJRSPP) (32) with calculated molecular 
weights of 36.91 kDa and 33.37 kDa, respectively.   
 
Electron crystallography is a well-suited method for answering structure-function 
questions such as how aspartyl proteases like SPP and PS function in the lipid bilayer. 
Structural data may provide critical insights into how a hydrolysis reaction occurs in a 
hydrophobic environment, how SPP determines which transmembrane domains to cleave, 
how drugs work to inhibit SPP function, and why SPP does not cleave all 




MATERIALS AND METHODS 
2.1 Phospholipid Preparation 
Lipid was prepared as previously described by Schmidt-Krey, 2007a (14). Briefly, a 10 
ml ampule containing dimyristoyl phosphatidycholine (DMPC) (Avanti®) in chloroform  
was pipetted into a clean round-bottom flask. A steady stream of nitrogen gas was used to 
evaporate the chloroform. The dried DMPC was resolublized with 3.5% sodium 
deoxycholate (Na-DOC). The solution was placed in a sonicator for five minutes or until 
the DMPC was completely dissolved. After sonication, the solution was aliquoted and 
stored at -20ºC until use. 
 
2.2 Lipid-to-Protein Ratio Determination 
The formula below was used to calculate the lipid-to-protein ratio (LPR) in a mol:mol 
ratio: 
LPR = [(Clipid * Vlipid) / MWlipid] ÷ [(Cprotein * Vprotein) / MWprotein]      (Equation 1) 
 
where Clipid is the concentration of DMPC, Vlipid is the volume of lipid, MWlipid is the 
molecular weight of lipid (Daltons), Cprotein is the concentration of DMPC, Vprotein is the 
volume of protein and MWprotein is the molecular weight of protein (Daltons). 
An example of a LPR (mol/mol) calculation can be seen below for a dialysis setup using 
75 μL of MCMJRSPP (33,370 Daltons), purified to 0.5 mg/mL, using 10 mg/mL DMPC, 
and solving to a final LPR of 18:  
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LPR 18 = [(10 mg/ml * Vlipid) / 678.15 Da] ÷ [(0.5 mg/ml * 75 μL) / 33,370 Da] = 1.371 
μl Vlipid 
2.3 Dialysis Set Up 
All glassware and dialysis clips (Spectrum Laboratories, INC) were washed with a 10% 
aqueous solution of Extran® MA01 Concentrate and rinsed with Millipore water prior to 
use. Eight to ten centimeter lengths of dialysis tubing (Spectrum Laboratories, INC) with 
a molecular weight cut-off of 12-14000 Daltons were hydrated in Millipore water for at 
least 15 minutes prior to use. Aliquots of protein, previously stored at -80ºC, were kept 
on ice during the experiment. Aliquots of DMPC lipid were allowed to thaw at room 
temperature. All dialysis trials used freshly prepared detergent-free dialysis buffer. Three 
buffers were used during crystallization trials of mSPP and MCMJRSPP; 50 mM HEPES 
[pH 7.5], 10 mM NaCl, 20% glycerol (buffer 1), 20 mM HEPES [pH 7.5], 100 mM 
NaCl, 5 mM MgCl2, 5 mM NaN3, 20% glycerol (buffer 2), and 20 mM MES [pH 6.0], 
100 mM NaCl, 5 mM MgCl2, 5 mM NaN3, 20% glycerol (buffer 3). The pH was adjusted 
using 5 N sodium hydroxide for all three dialysis buffers and was monitored with a pH 
meter (PHM250 Ion Analyzer, MeterLab®). The dialysis buffer (300 ml) was dispensed 
into 400 ml beakers. Next, 75 µl or 100 µl of mSPP or MCMJRSPP (overexpressed and 
purified in Dr. Raquel Lieberman’s laboratory by Dr. Jason Drury and Sibel Kalyoncu) 
was mixed on ice with varying amounts of lipid depending on the desired LPR (see LPR 
determination). The protein-lipid mix was gently vortexed and placed immediately back 
on ice. The dialysis tubing was rinsed with and placed into a fresh volume of Millipore 
water. After 10 minutes on ice, the dialysate was once more vortexed and aliquoted into 
dialysis tubing that was clipped at one end. A final dialysis clip was secured prior to 
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submerging in dialysis buffer. The beakers were covered with aluminum foil and placed 
in an incubator at 24ºC for 7-12 days without any stirring or dialysis buffer exchanges.  
 
2.4 Grid Preparation 
Mica was carbon-coated and grids were subsequently prepared as previously described 
(49). Briefly, freshly cleaved mica was placed in a carbon evaporator (Cressington 
Carbon Coater 208) and sharpened and flattened carbon rods were set in place. The 
evaporator was allowed to reach a vacuum of 10
-5
 atm prior to initializing manual carbon 
coating. After carbon coating was complete, the carbon-coated mica was placed in a 
desiccator until use. To carbon coat grids, grids (400 mesh nickel grids, SPI® Supplies) 
were submerged and arranged under water on a piece of Whatman filter paper. The 
carbon was floated onto the water from the mica and situated over the arranged grids. The 
water level was gradually decreased until the carbon was completely flat over the grids. 
The filter paper with the carbon-coated grids was then allowed to dry in the desiccator 
overnight prior to use. 
 
2.5 Negative Stain 
Negative staining was performed as previously described by Schmidt-Krey, 2007a (14). 
Grids were held in place with non-capillary tweezers (Dumont) as 2-2.5 µl of dialysate 
was pipetted onto each grid and allowed to incubate for two minutes. Each grid was 
gently blotted from the side with Whatman filter paper and immediately stained with 2 µl 
of 1% uranyl acetate (aqueous). The stain was blotted after 20-30 seconds. Grids were 





Screening negatively stained dialysis samples at the JEOL 1400 was performed as 
previously described (20). Briefly, the TEM was aligned prior to visualizing specimens. 
Samples were viewed initially at low magnifications (5-10kx). Promising coordinates 
within the grid plane were saved for further evaluation at intermediate magnifications 
(10-40kx). Intermediate magnification images were routinely captured with an Orius 
charge coupled device (CCD) Gatan side mount camera. Higher magnification images 
(50kx) were captured with an Ultrascan CCD camera. Images were evaluated using the 
Digital Micrograph (Gatan) software. Fast Fourier transforms (FFT) were used to assess 





TWO-DIMENSIONAL CRYSTALLIZATON OF SIGNAL PEPTIDE 
PEPTIDASE HOMOLOGUE FROM Haloarcula morismortui (mSPP) 
 
3.1. Two-dimensional crystallization trials of ammonium sulfate precipitation cut 
mSPP 
Protein purifications of 55-75% ammonium sulfate precipitation (ASP) cut mSPP were 
dialyzed against buffer 1 containing various NaCl concentrations between 10 to 100 mM 
and LPRs ranging from 10 to 40 (mol/mol) in dialysis experiments 9-14 (Table 1). 
Dialysis incubation was 7 to 9 days. Dialysis timing was considered partially based on 
the critical micelle concentration (CMC) of fos-choline (FC12) (1.5 mM) and previous 
dialysis trials (14). The starting concentration of FC12 is 0.1% w/v however, the final 
concentration of FC12 is unknown, due to concentrating mSPP in the final step with a 10 
kDa molecular weight cut-off (MWCO) amicon filter which is known to concentrate not 
only the protein but FC12 as well (46).  
 
It was observed that vesicles increased in size as NaCl concentrations decreased. At 10 
mM NaCl and LPR = 10 (Table 1: D14-3) (Figure 6a), vesicles were observed and 
evaluated with an FFT; strong reflections were observed (Figures 6b-e). Further dialysis 
experiments, with the same mSPP protein batch and additional purification batches, did 
not show reproducible results. Based on these limited results, it was determined that 




3.2 Two-dimensional crystallization trials of non-ammonium sulfate precipitation 
cut mSPP 
Non-ASP cut mSPP was dialyzed against buffer 2 conditions for 9 days and reconstituted 
in a lipid bilayer (Table 1, Figure 7). Membrane vesicles and sheets were observed. The 
best results were observed at LPR = 40, in which case FFTs showed strong reflections 
(Figures 7b and c). Thus mSPP can be crystallized into a lipid bilayer producing 50 nm x 
50 nm areas of 2D crystals under different buffer conditions and two LPRs, which may or 
may not be buffer-specific.  
 
3.3 Co-purified lipid in non-ammonium sulfate precipitations and ammonium 
sulfate precipitation cuts at LPR = 0 
Prior to dialysis 14, protein purification for 55-75% and 75-95% ASP cut and non-ASP 
cut batches of mSPP were inconsistently dialyzed at LPR = 0 to determine the presence 
of co-purified lipid. Early experiments that showed co-purified lipid were used for further 
dialysis experiments. However due to difficulties in reproducing results observed in 
dialysis 14-3, newly purified batches of ASP cut and non-ASP cut mSPP were dialyzed at 
LPR = 0 to determine the presence or absence of co-purified lipid (Figures 8a and b). 
Protein purification batches that showed co-purified lipid were not used for future 
dialysis experiments. Dialyzing protein at LPR = 0 was completed to find a consistent 
result where protein precipitated. 
 
3.4 Testing of reconstitution and two-dimensional crystallization parameters 
Protein concentrations between 0.1-1.0 mg/ml were tested and showed no differences 
following dialysis. Various mSPP purifications were used in 2D crystallization trials, 
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these included 0-55%, 55-75% and 75-95% ASP cuts, and concentrated and 
unconcentrated mSPP purifications. There were no remarkable patterns noted when 
various ASP cut fractions were dialyzed. Protein that was concentrated using different 
MWCO concentrators, such as 10 kDa, 30 kDa, and 100 kDa, did not show any 
significant differences. No differences were noted based on whether or not the protein 
was freshly purified or previously frozen and subsequently thawed for dialysis. A 
temperature change from 24°C to 28°C during dialysis incubation did not produce 
remarkably different results. Different detergents and detergent concentrations did not 
produce significant results. A summary of conditions tested and best conditions identified 
can be found in Table 2. 
 
3.5 Discussion 
The LPR appears to be important in the 2D crystallization of mSPP. Lower LPRs 
increase membrane crystallinity (Table 1 and 2), but needed adjustment between batches. 
Due to the limited success with mSPP, it cannot be concluded whether crystallization 
occurs entirely in an LPR-dependent manner. 
 
Buffers 1 and 2 were found to produce good membrane morphology and sizes when 
tested on 55-75% ASP and non-ASP cut mSPP, respectively. Weak to strong reflections 
were observed in selected vesicles (Figures 6 and 7). Previously, mSPP was crystallized 
with buffer 1. The combination of a decrease in HEPES concentration, increase in NaCl 
and/or additional buffer component, magnesium chloride (MgCl2), may have contributed 
to improved membrane morphology and crystal formation.    
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The vesicles that were slightly tubular showed the best reflections for mSPP for dialysis 
conditions 14-3 (Figure 6). For dialysis 68-2 (Figure 7), there were electron dense 
aggregates and vesicles. These vesicles showed weak to strong reflections. 
 
In crystallization trials of mSPP, two detergents were utilized, FC12 and Triton-X-100 
(CMC 0.10-0.16% w/v). FC12 was the solubilizing detergent that worked most 
successfully. However during the course of the crystallization trials of mSPP, Triton-X-
100 was used. The use of Triton-X-100 did not result in mSPP reconstitution or 2D 
crystallization 
 
During the crystallization trials, variations in the FC12 concentration were tested from 
0.1% to 2.0%. The percentage of FC12 increases when a 10 kDa MWCO is used to 
concentrate FC12 solubilized protein (46). This may or may not have contributed to 
inconsistencies amongst batches of mSPP. None of the conditions where FC12 was 
varied resulted in mSPP reconstitution or 2D crystallization.  
 
In addition to variations in protein concentrations, various ASP cuts were tested in 
crystallization trials for mSPP. Ammonium sulfate precipitation changes the solubility of 
the protein in solution. As the percentage of ammonium sulfate is increased protein 
precipitates. Collected fractions are designated according to the percent of ammonium 
sulfate used to precipitate protein. In the case of mSPP, various cuts were collected 
between 0-55%, 55-75% and 75-95% as well as non-ASP cut mSPP to determine if 
different cuts would crystallize more readily than others.  
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Amongst the ASP cuts and non-ASP cut, inconsistent results were observed when protein 
was dialyzed at LPR = 0. Two different purifications using the same ASP cut would 
result in precipitated protein and co-purified lipid after dialysis. The inconsistencies 
observed with mSPP made it impossible to determine which combination of variables 
contributed to the results observed in dialysis 14-3 and 68-2 (Figures 6 and 7).  
 
There is not enough data to conclude whether co-purified lipid played a negative or 
positive role in the crystallization of mSPP. Further investigations with new batches of 
purified protein and buffer conditions may shed light on how co-purified lipid contributes 
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Figure 6. mSPP crystallization trials dialysis 14-3. a) Dialysis 14-3 at LPR = 10 
produced vesicles. Scale bar corresponds to 0.2 µm. b-e) Higher magnifications of 
vesicles. The boxed areas in the high magnification images (b and d) correspond to the 
FFTs (c and e). Scale bar corresponds to 50 nm. FFTs revealed weak pairs of reflections 























Figure 7. mSPP crystallization trials dialysis 68-2. a) Dialysis 68-2 at LPR = 40 
produced vesicles. Scale bar corresponds to 0.2 μm b and c) High magnification of 
vesicles and associated FFT. The boxed area in the high magnification image (b) 






Figure 8.  Representative images of precipitated protein and co-purified lipid. a) An 
example of precipitated mSPP at LPR = 0. b) An example of electron-dense membrane 
structures at LPR = 0 indicating co-purified endogenous lipid. Both scale bars correspond 





Table 2. Summary of conditions tested during 2D crystallization trials of mSPP. 
*Column 3 outlines the best set of conditions (buffer 1) identified for crystallizing 55-
75% ASP cut mSPP. **Column 4 outlines the best set of conditions (buffer 2) identified 
for crystallizing non-ASP cut. 
 
  
Parameters Range Tested *Buffer 1 **Buffer 2 
pH 7.5 7.5 7.5 
Protein Concentration 
(mg/ml) 
0.1-1  1 1 
ASP cut (%) 
0-55%, 55-75%, 
75-95% 
55-75% Non-ASP Cut 
Lipid 
DMPC (1 mg/ml 
and 10 mg/ml) 
1 mg/ml 10 mg/ml 




FC12 FC12  
Detergent 
Concentrations (%) 
0.1-2.0 0.1 0.1 









Buffer: HEPES (pH 7.5) 
50 mM, 20 mM 
HEPES 
50 mM HEPES 20 mM HEPES 
NaCl (mM) 10-500 10 100 
MgCl2 (mM) 5 N/A 5 
NaN3 (mM) 5 N/A 5 




TWO-DIMENSIONAL CRYSTALLIZAITON OF SIGNAL PEPTIDE 
PEPTIDASE HOMOLOGUE FROM Methanoculleus marisnigri JR1 
(MCMJRSPP)  
 
4.1 Membrane morphologies and sizes of MCMJRSPP proteoliposomes and two-
dimensional crystals 
Batch 1 purified protein of MCMJRSPP reconstituted into exogenous lipid producing 
ideal membrane morphology over a range of LPRs (Table 3, D3-4). At LPRs ranging 
from 20 to 300, sheets, vesicles and tubular membranes were observed. Weak reflections 
were observed when membranes were assessed with an FFT to identify long-range order.  
Membrane sizes ranged from 100 nm to 10-15 µm in some instances (Figure 9a). At 
LPRs above 40, membrane morphology had a corrugated appearance potentially 
indicating ordered lipid crystallization (Figures 9b and c).  
 
4.2 Two-dimensional crystallization of MCMJRSPP 
Crystallization was detected after 9-12 days of dialysis at LPRs between 13 to 40. The 
dialysis timing was based on the CMC of n-Dodecyl-β-D-Maltopyranoside (DDM) 
(0.17mM) and 2D crystallization experiments described previously (19).  Additionally, 
an extended dialysis time was used since the final concentration of DDM is unknown due 
to concentrating MCMJRSPP to the appropriate concentration with a 10 kDa MWCO 






Vesicles and sheets associated and unassociated with electron dense 
aggregates/membrane structures showed crystallinity (Figures 11, 12, 14, 16). LPRs 
above 20 showed a decrease in electron dense aggregates and crystallinity. For batches 4-
6 and 8, crystallinity was detected within a narrow LPR range of 13 to 25. 
 
4.3 Reproducibility of MCMJRSPP two-dimensional crystallization 
Protein purification batches 4-6 and 8 reproducibly resulted in good membrane 
morphology that included sheets and vesicles (Table 3; Figures 11, 12, 14, 16). Amongst 
these four purifications in a narrow LPR range between 13 to 25, weak to strong 
reflections were observed (Figures 11, 12 and 14). In addition, high contrast crystalline 
patches were observed, starting with batch 4 (Table 4: D10-6). The high contrast 
crystalline patches were randomly dispersed in sheets and vesicles, ranging in size from 
50 nm x 50 nm to 200 nm x 200 nm (Figures 11a-c). Images of negatively stained high 
contrast crystalline patches at high magnification showed strong first and second
 
order 
reflections by FFT (Figures 11d and e). Batches 5, 6 and 8 also produced high contrast 
crystalline patches (Table 4: D13-6, D18-3, and D20-3). A summary of parameters tested 
is outlined in Table 4. 
 
4.4 Two-dimensional crystallization buffer conditions 
Buffers 2 and 3 were used to crystallize MCMJRSPP. Buffer 2 was tested for dialysis 
experiments 1-8 and 10-15. Batch 1 under buffer 2 conditions produced membranes. 
However, batches 2 and 3 did not reproduce these results. New lipid preparations were 
compared and ruled out as possible sources for the discrepancies observed. Buffer 3, 
replacing 20 mM HEPES [pH 7.5] in buffer 2 with 20 mM MES [pH 6.0], was utilized to 
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determine if batches 2 and 3 would crystallize under slightly different buffer conditions. 
Batch 2 under buffer 3 conditions (Table 3, D9-2) produced good membrane morphology 
and strong reflections (Figures 10a and b). However, under the same conditions batch 3 
(Table 3, D9-6) did not yield the same results. Following these results, it was determined 
that a buffer exchange, following the purification before the gel filtration step differed. 
This difference was corrected in subsequent purifications. It was determined that buffer 3 
produced comparable or better membrane morphologies and high contrast crystalline 
patches compared to buffer 2.   
 
4.5 Projection maps of MCMJRSPP. 
Electron micrographs of negatively stained high contrast crystalline patches from dialysis 
conditions D10-6 and D18-3 were processed with 2dx (47) to produce projection maps. 
Images 17b and d were processed and produced the projection structures and maps seen 
in Figures 17a, c, d, and f. The unit cell dimensions are a = 178 Å, b = 160 Å, ɣ = 92 Å 
and a = 175 Å, b = 167 Å ɣ = 92 Å (Table 5), respectively. Both projection maps have p1 
symmetry and are limited to 16 Å resolution due to the stain.  
 
The monomer dimensions for D10-6 are approximately 80 Å by 75 Å.The measurements 
for D18-3 are approximately 70 Å by 70 Å. These dimensions are based on preliminary 
projection maps. Three strong densities appear to represent monomers. In both projection 
maps, low-contrast, elongated densities protrude from each monomer.  
 
4.6 Discussion 
The LPR was pivotal to obtaining 2D crystals of MCMJRSPP. Broad ranges of 
membrane morphologies and sizes were observed at LPRs between 1 to 300 during 
MCMJRSPP crystallization trials (Table 3 and 4). The best results with batch 1 were 
obtained at LPR = 40. From these initial crystallization trial results, it was determined 
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that crystallinity increased as the LPR decreased. Additional batches (4-6 and 8) showed 
reproducibility at LPR = 40 and lower LPRs between 13 to 25. The narrow range of 
LPRs between 13 to 25 produced high contrast crystalline patches indicating 
MCMJRSPP crystallizes in an LPR-dependent manner. LPR-dependency has been 
observed previously with membrane proteins (48). 
 
Two buffers were tested during the crystallization of MCMJRSPP. Buffer 2 was 
formulated based on previous 2D crystallization with 20% glycerol (49, 50, 51), along 
with previous dialysis trials using mSPP (HEPES, NaCl, and pH), and buffer components 
(MES and NaN3) (52).  
 
Buffer 2 worked well with batch 1 but not with purified protein from batches 2 and 3. 
Dialysis was repeated again for these two batches to rule out human and lipid preparation 
error. In addition, the protein purification protocol was reviewed to identify any 
discrepancies between purification batches 1, 2 and 3. While other possibilities for error 
were being ruled out, the buffer components were changed slightly, MES was substituted 
for HEPES and the pH was changed from 7.5 to 6.0 to create buffer 3 (52). Batches 2 and 
3 were dialyzed against buffer 3 conditions and it was found that batch 2 showed decent 
membrane morphology (less than 1 m to several microns in size) with weak to good 
reflections while batch 3 did not. Following success with buffer 3, both buffers were 
tested until it was determined that buffer 3 gave better results in terms of membrane 
morphology and crystallinity (Table 3: D14-5 and D14-6). Dialysis 14-5 under buffer 2 
conditions at LPR = 20 produced vesicles and sheets less than 50 nm to 1 μm in size and 
did not contain high contrast crystalline patches. In contrast dialysis 14-6 under buffer 3 
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conditions and at the same LPR produced vesicles and sheets that measured less than 50 
nm to 1-2μm and contained high contrast crystalline patches.  
 
Membrane morphology for MCMJRSPP crystallization trials varied greatly with high 
LPRs (above 40) producing vesicle, sheet and tubular morphologies that were less than a 
50 nm to 10-15 µm in length. However, as the LPR decreased, smaller membrane 
morphologies were observed, less than 50 nm up to 1-2 µm. With the decrease in LPR, 
two types of crystalline regions were observed within membrane sheets and vesicles. 
Visible high contrast crystalline patches were observed in 10 to 20% of vesicles and 
sheets at a nominal magnification of 40,000 to 60,000x. The other type of crystallinity 
was only evident when membranes were scanned with an FFT in Digital Micrograph.  
 
It is unclear how the high contrast crystalline patches are forming within vesicles and 
sheets. The patches do not appear to be a moiré due to two lattices based on observations 
of the FFTs. The membranes do not appear to be stacked and there is an absence of 
multiple edges to indicate that such an event is occurring.   
 
The best crystals were observed when there was a presence of aggregate. The aggregate 
would have vesicles attached around the perimeter of its electron dense structure (Figure 
16a). Within these vesicles and sheets, attached to or scattered around the aggregate, high 
contrast crystalline patches were observed that showed first and second order reflections 
(Figure 14).  
 
During the crystallization trials two aspects of the purification process impacted the 
dialysis results. The first was noted during the purification of batches 2 and 3 of 
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MCMJRSPP. Batch one was eluted from a Ni-NTA column and a buffer exchange was 
completed before gel filtration. However, for batches 2 and 3, a buffer exchange was not 
completed which impacted the reproducibility. The absence of the buffer exchange may 
have negatively impacted the pH or dialysis buffer components.  
  
The other aspect that impacted crystallization conditions appears to have been the use of 
a new batch of n-dodecyl-β-D-maltopyranoside (DDM) detergent. Batch 7 purification 
was completed with a new batch of DDM. Dialysis of batch 7 resulted in aggregate and 
no vesicles. These results were similar to LPRs lower than 13 tested with previous 
batches where the grid squares contain mostly aggregate and no vesicles.  
 
For batches tested prior to batch 7, as the LPR is increased over 13, more vesicles 
appeared associated and unassociated with the electron dense aggregate. Eventually, as 
the LPR surpasses 20, vesicles were present on the grid with very little aggregate. Upon 
testing of high LPRs (20, 25 and 30) for batch 7, it was theorized the optimal LPR for 
batch 7 was slightly increased due to a new batch of DDM. The new DDM most likely 
succeeded in removing more bacterial lipid during purification than the previous batch.  
 
MCMJRSPP was dialyzed for 9 to 12 days to completely removed DDM by dialysis. The 
reason for the long dialysis is due to the low critical micelle concentration of DDM. 
Other researchers using DDM to solubilize membrane proteins have found DDM removal 
takes 12-13 days using dialysis blocks and exchanging dialysis buffer daily (53). The 
daily buffer exchanges were necessary due to the small amount of buffer that can be 
contained within the dialysis block. In the case of MCMJRSPP, dialysis blocks were not 
used. A volume of 300 ml was used in all dialysis trials. 
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If detergent is not adequately removed during dialysis, the detergent will degrade 
membranes and crystals over time. An excess of detergent can easily be tested by 
aliquoting 2 µl of dialysate onto a grid and observing how the drop spreads over the grid.  
 
Protein purifications of MCMJRSPP contained co-purified lipid (Table 4, far right 
column). The presence of co-purified lipid did not seem to have a substantial effect on the 
LPR. All other batches tested at LPR = 0 showed membrane structures. Based on the 
reproducibility between batches, 4-6 and 8, the amount of endogenous lipid appears to be 
similar between batches and did not have a significant influence on the outcome of 
crystallization trials investigated thus far, as the optimal LPR to produce both membranes 
and crystals is a narrow range between 13-25. 
 
It is unclear whether or not the amount of lipid had a significant impact on the spacing of 
the protein in the projection maps. More images will be processed at different LPRs to 








Table 3. 2D crystallization parameters for different purification batches of MCMJRSPP. 
*Batches 2 and 3 (B2 and B3) were purified differently compared to the other batches 



















Results LPR = 0 Results 




Vesicles, less than 50 nm to microns. Lipid 
crystals. Weak reflections. Figure 9 
Precipitated protein/ No 
aggregate. Bacteria present 




Vesicles and sheets, less than 50 nm to microns. 
Weak reflections. Figure 10 
Co-purified lipid/No 
precipitated protein 
D9-6 B3* 40 
Buffer 
3 
10 No membranes. Figure 10 
Co-purified lipid/No 
precipitated protein 




Vesicles, less than 50 nm to microns. High 
contrast crystalline patches randomly dispersed 
in vesicles. Strong reflections. Figure 11 
Co-purified lipid/No 
precipitated protein 




Vesicles and sheets, less than 50 nm to 2 μm. 
High contrast crystalline patches. Strong 
reflections. Vesicles associated and unassociated 
with e-dense aggregates. Figure 12 
Co-purified lipid/No 
precipitated protein 




Vesicles, less than 50 nm to microns. High 
contrast crystalline patches. Strong reflections. 
Vesicles associated and unassociated with 
electron dense aggregates. No Figures 
Co-purified lipid/No 
precipitated protein 




Vesicles less than 50 nm to 1 m. No high 
contrast crystalline patches observed. Weak 
reflections. Vesicles unassociated and associated 
with electron dense aggregate. Figure 13 
N/A 




Vesicles, less than 50 nm to 1-2m. High 
contrast crystalline patches. Strong reflections. 
Vesicles associated and unassociated with 
minimal electron dense aggregates. Figure 13 
N/A 




Vesicles and sheets, less 50 nm to 1-2 m. High 
contrast crystalline patches. Strong reflections. 
Vesicles associated and unassociated with 
electron dense aggregates. Figure 14 
N/A 
D17 B7** 20 
Buffer 
3 
12 Electron dense aggregate. Figure 15 
Co-purified lipid/No 
precipitated protein 




Electron dense aggregate with minimal 
membrane vesicles, less than 500 nm. Figure 15 
Co-purified lipid/No 
precipitated protein 




Vesicles, less than 500 nm. High contrast 
crystalline patches. Strong reflections. Vesicles 
associated and unassociated with electron dense 





Table 4. Summary of conditions tested during 2D crystallization trials of MCMJRSPP. 

















Parameters Range Tested Buffer 3* 
pH 7.5 and 6.0 6.0 
Protein Concentration (mg/ml) 0.5 mg/ml 0.5 mg/ml 
Protein Purification Batches 1-8 6 
Lipid (10 mg/ml) in 3.5% Na-DOC DMPC DMPC 
LPR (mol/mol) 1 - 300 13-25 
Detergent DDM DDM 
Temperatures (ºC) 24ºC 24ºC 
Dialysis Time (days) 9-12 9-12 




Buffer 2 HEPES (pH 7.5) and 
Buffer 3 MES (6.0) 
20 mM HEPES, 20 
mM MES 
20 mM MES 
NaCl (mM) 100 100 
MgCl2 (mM) 5 5 
Glycerol (%) (v/v) 20 20 






































Figure 9. 2D crystallization trial of MCMJRSPP dialysis 3-4. a) Representative overview 
image of batch 1 reconstituted at LPR = 40 under buffer 2 conditions. Vesicles and 
tubular morphologies ranged in size up to from less than 1 m to many microns in length. 
Scale bar corresponds to 0.5 m. b and c) High magnification of vesicle showing a 
corrugated pattern with FFT. The boxed area in the high magnification image (b) 







Figure 10. 2D crystallization trial of MCMJR SPP dialysis batch 2 compared to batch 3 
under the same conditions at LPR = 40 using buffer 3. a) Representative image of batch 
2. Scattered vesicles and sheets ranging in size. Scale bar corresponds to 1 m. b) No 
vesicles or sheets were observed in Batch 3 under the same conditions. Scale bar 























Figure 11. 2D crystallization trials of MCMJR SPP dialysis 10-6. a-c) Overview images 
of batch 4 at LPR = 20 under buffer 2 conditions. Sheets and vesicles are seen with high 
contrast crystalline patches present. Scale bars correspond to 100 nm (a, b) and 0.5 m 
(c). d) High magnification image of area circled in overview (c). Scale bar corresponds to 
20 nm. e) FFT showing strong first and second order reflections (e). The boxed area in 























Figure 12. 2D crystallization trials of MCMJRSPP dialysis 12-6. a) Overview image of 
batch 4 crystallized at LPR = 15 under buffer 2 conditions. Vesicles and sheets are seen 
attached to electron dense aggregate. Circled area shows high contrast crystalline patch. 
Scale bar correspond to 200 nm. b) High magnification image of circled area. c) FFT 
showing strong reflections of high contrast crystalline patch. The boxed area in the high 












Figure 13. 2D crystallization trials of MCMJRSPP dialysis 14-5 and 14-6. a) 
Representative overview image of batch 6 at LPR = 20 under buffer 2 conditions 
compared to overview image of batch 6 at LPR = 20 under buffer 3 conditions (b). Buffer 
3 shows an increase in membrane morphologies compared to results from buffer 2. Scale 





Figure 14. 2D crystallization trials of MCMJRSPP dialysis 18-3. a and b) Representative 
overviews of batch 6 at LPR = 18 under buffer 3 conditions. Scale bar corresponds to 0.2 
m. c-f) High magnification images with high contrast crystalline patches. The boxed 
areas in the high magnification images (c and e) correspond to the FFTs (d and f). Scale 






































































Figure 15. 2D crystallization trials of MCMJRSPP dialysis 17-1 and 19-3. a) 
Representative overview image of 17-1 at LPR = 20 under buffer 3 conditions. Increase 
in membrane structures compared to previous batches dialyzed at LPR = 20. b) Dialysis 
19-3 shows an increase in vesicles compared to 17-1. The LPR was increased from 20 to 
35. The skewed LPR resulted from additional endogenous co-purified lipid being 




Figure 16. 2D crystallization trials of MCMJR SPP batch 8 at LPR = 20 under buffer 3 
conditions. a) Vesicles associated and unassociated with electron dense aggregate. Scale 
bar corresponds to 1 m. b) Vesicles with high contrast crystalline patches (circles). 
































Figure 17. Projection map of MCMJRSPP dialysis 10-6 and 18-3 a) Shows the 
projection map to 16Å. The unit cell dimensions are a = 178 Å, b = 160 Å, ɣ = 92 Å. 
Three strong densities can be seen in the projection map around the pore. Scale bar 
corresponds to 20 Å. b) Negatively stained crystalline MCMJRSPP vesicle. High contrast 
crystalline lattice is visible within in the membrane of the vesicle. Scale bar corresponds 
to 20 nm. c) Shows the resulting projection structure. d) Shows the projection map to 16 
Å resolution. The unit cell dimensions are a = 175 Å, b = 167 Å, ɣ = 92 Å. Three strong 
densities can be seen in the projection map with a minute pore. Scale bar corresponds to 
20 Å. e) A negatively stained crystalline MCMJRSPP vesicle. Scale bar corresponds to 

















































Table 5. Electron crystallographic data for MCMJRSPP D10-6 and D18-3. 
Electron Crystallographic Data for D10-6 and D18-3 
Imaging Conditions  
   Nominal magnification / camera length (cm) 65431.4 / 100 
   High Tension (kV) 120 
   Electron Source Tungsten 
   Defocus (Å) D10-6 
   Defocus (Å) D18-3 
x = 22293.3, y = 20983.9  
x = 10524.6, y = 13925.3 
   Astigmatic (deg.) D10-6 
   Astigmatic (deg.) D18-3 
57.04 
23.92 
Image Processing  
   Scan Area (pixels) 2048 x 2048 
   Pixel Size (µm) 14 
   Program System 2dx 
Crystal Parameters  
   Unit cell (Å; deg.) D10-6 
   Unit cell (Å; deg.) D18-3 
a = 178, b = 160, = 92 
a = 175, b = 167, = 92 







Electron crystallography was used to investigate achaea aspartyl protease SPPs from 
Haloarcula morismortui and Methanoculleus marisnigri JR1. This is the first time an 
SPP homologue has been crystallized in 2D. It was shown that MCMJRSPP reproducibly 
crystallized within a narrow LPR range of 13 to 25 under specific buffer conditions 
(Table 4). Within this narrow LPR range, high contrast crystalline patches were observed 
and processed using 2dx (47). In contrast to MCMJRSPP, high contrast crystalline 
patches were not observed in any of the conditions tested for mSPP. Overall, mSPP 
showed limited success during 2D crystallization trials. Optimizing dialysis conditions 
using MCMJRSPP may potentially provide insight and facilitate reproducible and 
improved crystallization of mSPP.  
 
DMPC was utilized for both mSPP and MCMJRSPP. The lipid, solubilized in detergent, 
is added based on the LPR calculations (see methods) to the detergent-solubilized 
protein. As the detergent is removed during dialysis, the membrane proteins will 
reconstitute into a lipid bilayer. When no lipid is added, the membrane proteins will 
either precipitate as the detergent is dialyzed, or it will form aggregates, membrane 
structures, and/or electron dense amorphous structures indicating co-purified lipid. The 
presence of aggregates and membrane structures indicate that not all of the endogenous 
lipid was removed during the purification process. Ideally, as much endogenous lipid as 
possible should be removed prior to starting crystallization trials. In both crystallization 
trials, co-purified lipid was present. Only in the case of MCMJRSPP, did the presence of 
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endogenous lipid not appear to have a substantial effect on reproducibility. In attempts to 
reproduce membrane morphology and crystallinity observed with dialysis 14-3 for mSPP, 
multiple batches of 55-75% ASP cut mSPP produced different results within a narrow 
LPR range and at the same LPR.  
 
The protein concentration was kept constant at 0.5 mg/ml for all crystallization 
conditions involving MCMJRSPP. Future tests will involve varying the protein 
concentration. Unlike MCMJRSPP, wide ranges of protein concentrations were tested for 
mSPP from 0.1-1 mg/ml. None of these variations contributed to remarkable changes. 
Other groups have found that testing a range of protein concentrations is critical; such 
was the case with secondary citrate/sodium symporter CitS (54, 55). 
  
Images of negatively stained crystals for MCMJRSPP were processed using 2dx (47). 
The following unit cell dimensions were calculated; a = 178 Å, b = 160 Å, ɣ = 92 Å and 
a = 175 Å, b = 167 Å ɣ = 92 Å (Table 5). Both projection maps have p1 symmetry (no 
symmetry imposed) and are limited to 16 Å resolution because they are negatively 
stained. Negative stain imposes a limit on the resolution by surrounding and coating the 
protein crystal. Electron cryo-microscopy is used to collect higher frequency data because 
the sample is in frozen hydrated buffer and data is collected under low does conditions. 
The monomer dimensions for Figures 17 a and d were 80 Å by 75 Å and 70 Å by 70 Å.  
 
There are currently two 3D structures of aspartyl proteases related to mSPP and 
MCMJRSPP. The presenilin homolog (PSH) variant determined by X-ray 
crystallography to 3.3 Å resolution (32) and human SPP determined by signal particle 
analysis (31).  
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PSH was purified from Methanoculleus marisnigri JR1 and was engineered to contain 
mutations and loop deletions to improve stability in solution and crystallization; this 
however did not affect protease activity. The total molecular weight of PSH was 
approximately 158 kDa, indicating oligomerization. Li and colleagues calculated the 
following dimensions for one molecule of PSH; 50 Å in length, 40 Å in width and height 
(32). In comparison, a monomer of MCMJRSPP had slightly larger dimensions (70 Å by 
80 Å) compared to a monomer of PSH (50 Å x 40 Å). Both MCMJRSPP and PSH are 
from the same archaeon bacterium, Methanoculleus marisnigri JR1. The difference in 
size could be related to the sequence engineering that was necessary to crystallize PSH. 
Five missense mutations were introduced mostly in the surface loops; these loops were 
also subjected to proteolysis by V8 protease. These mutations and loop deletions did not 
affect PSH protease activity.  
 
Single particle analysis showed a homotetramer, which is active in vitro (31). Given the 
absence of a lipid bilayer and potentially due to signal particle analysis used, the 
homotetramer may not be the active structure in vivo. Previous work has shown that 
endogenous human SPP functions as an active dimer in vivo (30). Miyashita and 
colleagues showed DDM-solubilized SPP produces a single band at 200 kDa in a Blue-
Native PAGE, indicating a multimeric complex like PSH. Additional Blue-Native PAGE 
data of DDM-solubilized Drosophila SPP showed a band at 180 kDa, indicating that 
Drosophila SPP forms a multimeric complex similar to human SPP (31).  
 
The bullet shaped homotetramer of human SPP measures 85 Å in length and width and 
130 Å in height. In comparison, MCMJRSPP has slightly shorter dimensions than human 
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SPP. MCMJRSPP is an archaeal SPP and may be structurally different compared to the 
human SPP described by Miyashita and colleagues. 






Archaeal homologues of SPP, MCMJRSPP and mSPP were crystallized in 2D. 
MCMJRSPP crystallized in an LPR-dependent manner, forming high contrast crystalline 
patches. These crystalline patches measured up to 200 nm x 200 nm and showed unit cell 
measurements of a = 178 Å, b = 160 Å, ɣ = 92 Å and a = 175 Å, b = 167 Å ɣ = 92 Å.  
Projection maps at 16 Å resolution showed three electron densities per monomer. Based 
on the preliminary projection maps, MCMJRSPP may be a dimer. Further optimization is 
planned to obtain larger lattices for processing and for collecting cryo-EM data to 
determine the structure at higher resolution and in 3D.  
 
Additional crystallization trials are necessary to determine whether the crystallization 
conditions for MCMJRSPP are applicable to mSPP crystallization. Preliminary data 
appears to indicate that crystallization of mSPP may be possible with conditions used for 
MCMJRSPP. Other SPP/SPPL may crystallize under the same or similar conditions. 
 
Further 2D crystallization trials are planned to answer pivotal questions about the 
structure and function of SPP, such as how do aspartyl proteases hydrolyze peptide bonds 
in a hydrophobic environment, how do aspartyl proteases determine which signal 
peptides and other membrane proteins to cleave, and finally how will a structure of an 





1.         Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. (2001). Predicting 
transmembrane protein topology with a hidden Markov model: application to complete 
genomes. J Mol Biol 305(3): 567-580. 
  
2.         Alberts, B. (2002). Molecular Biology of the Cell. New York, Garland Science. 
  
3.         Yildirim, M. A., Goh, K., Cusick, M. E., Barabasi, A., & Vidal, M. (2007). Drug-
target network. Nat Biotechnol 25(10): 1119-1126. 
  
4.         Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006). How many drug 
targets are there? Nat Rev Drug Discov 5(12): 993-996. 
  
5.         Fairman, J. W., Noinaj, N., & Buchanan, S. K. (2011). The structural biology of 
beta-barrel membrane proteins: a summary of recent reports. Curr Opin Struct Biol 21(4): 
523-531. 
  
6.         Bordag, N & Keller, S. (2010). Alpha-helical transmembrane peptides: a Divide 
and Conquer approach to membrane proteins. Chem Phys Lipids 163:1-26. 
  
7.         Henderson, R. & Unwin, P. N. (1975). Three-dimensional model of purple 
membrane obtained by electron microscopy. Nature 257(5521): 28-32. 
  
8.         Ubarretxena-Belandia, I and Stokes, D. L. (2010). Present and future of 
membrane protein structure determination by electron crystallography. Adv Protein Chem 
Struct Biol 81:33-60. 
  
9.         Kühlbrandt, W. (2012). Combining Cryo-EM and X-ray Crystallography to Study 
Membrane Protein Structure and Function. Macromolecular Crystallography: 
Deciphering the Structure, Function and Dynamics of Biological Molecules. Ed. Maria 
Armenia Carronda and Paola Spadon. NATO Science for Peace and Security Series A: 
Chemistry and Biology. Springer, 2012, 93-101. 
  
10.       Oesterhelt, D. & Stoeckenius, W. (1971). Rhodopsin-like protein from the purple 
membrane of Halobacterium halobium. Nature New Biol 233: 149-152.     
11.       Walz, T. (1998). Electron crystallography of two-dimensional crystals of 
membrane proteins. J Struct Biol 121: 142-161. 
  
12.       Junge, F., Schneider, B., Reckel, S., Schwarz, D., Dotsch, V., & Bernhard, F. 




13.       Vinothkumar, K. R., Edwards, P. C., & Strandfuss, J. (2013). Practical aspects in 
expression and purification of membrane proteins for structural analysis. Methods Mol 
Biol 955: 17-30. 
  
14.       Schmidt-Krey, I. (2007a). Electron crystallography of membrane proteins: two-
dimensional crystallization and screening by electron microscopy. Methods 41(4): 417-
426. 
  
15.       Dreaden, T. M., Metcalfe, M. G., Kim, L. Y., Johnson, M. C., Barry, B. A., & 
Schmidt-Krey, I. (2013). Screening for two-dimensional crystals by transmission electron 
microscopy of negatively stained samples. Methods Mol Biol 955: 73-101. 
  
16.       Johnson, M. C., Dreaden, T. M., Kim, L. Y., Rudolph, F., Barry, B. A., & 
Schmidt-Krey, I. (2013). Two-dimensional crystallization of membrane proteins by 
reconstitution through dialysis. Methods Mol Biol 955: 31-58. 
  
17.       Fujiyoshi, Y. (2013). Low dose techniques and cryo-electron microscopy. 
Methods Mol Biol 955: 103-118. 
  
18.       Avila-Sakar, A., Li, X., Zheng, S. Q., & Cheng, Y. (2013). Recording high-
resolution images of two-dimensional crystals of membrane proteins. Methods Mol Biol 
955: 129-152. 
  
19.       Arheit, M. (2013). Image processing of 2D crystal images. Methods Mol Biol 955: 
171-194. 
  
20.       Erez, E., Fass, D., & Bibi, E. (2009). How intramembrane proteases bury 
hydrolytic reactions in the membrane. Nature 459(7245): 371-378. 
  
21.       Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K., & Martoglio, B. (2002). 
Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 
296(5576): 2215-2218. 
  
22.       Ponting, C. P., Hutton, M., Nyborg, A., Baker, M., Jansen, K., & Golde, T. E. 
(2002). Identification of a novel family of presenilin homologues. Hum Mol Genet 11(9): 
1037-1044. 
  
23.       Grigorenko, A. P., Moliaka, Y. K., Korovaitseva, H. I., & Rogaev, E. (2002). 
Novel class of polytopic proteins with domains associated with putative protease activity. 
Biochemistry (Mosc) 67(7): 826-835. 
  
24.       Friedmann, E., Lemberg, M. K., Weihofen, A., Dev, K. K., Dengler, U., Rovelli, 
G., &  Martoglio, B. (2004). Consensus analysis of signal peptide peptidase and 
homologous human aspartic proteases reveals opposite topology of catalytic domains 
compared with presenilins. J Biol Chem 279(49): 50790-50798. 
  
 52 
25.       Fluhrer, R., Grammer, G., Israel, L., Condron, M. M., Haffner, C., Friedmann, E., 
Böhland, C., Imhof, A., Martoglio, B., Teplow, D. B., & Haass, C. (2006). A gamma-
secretase-like intramembrane cleavage of TNF alpha by the GxGD aspartyl protease 
SPPL2b. Nat Cell Biol 8(8): 894-896. 
  
26.       Friedmann, E., Hauben, E., Maylandt, K., Schleeger, S., Vreugde, S., 
Lichtenthaler, S. F., Kuhn, P.H., Stauffer, D., Rovelli, G., & Martoglio, B. (2006). 
SPPL2a and SPPL2b promote intramembrane proteolysis of TNF alpha in activated 
dendritic cells to trigger IL-12 production. Nat Cell Biol 8(8): 843-848. 
  
27.       Kirkin, V., Cahuzac, N., Guardiola-Serrano, F., Huault, S., Lückerath, K., 
Friedmann, E., Novac, N., Wels, W. S., Martoglio, B., Hueber, A.O., & Zörnig, M. 
(2007). The Fas ligand intracellular domain is released by ADAM10 and SPPL2a 
cleavage in T-cells. Cell Death Differ 14(9): 1678-1687. 
  
28.       Voss, M., Fukumori, A., Kuhn, P.H., Künzel, U., Klier, B., Grammer, G., Haug-
Kröper, M., Kremmer, E., Lichtenthaler, S. F., Steiner, H., Schröder, B., Haass, C., & 
Fluhrer, R. (2012). Foamy virus envelope protein is a substrate for signal peptide 
peptidase-like 3 (SPPL3). J Biol Chem 287(52): 43401-43409. 
            
29.       Lemberg, M. K. & Martoglio, B. (2002). Requirements for signal peptide 
peptidase-catalyzed intramembrane proteolysis. Mol Cell 10(4): 735-744. 
  
30.       Nyborg, A. C., Kornilova, A. Y., Jansen, K., Ladd, T.B., Wolfe, M.S., & Golde, 
T. E. (2004). Signal peptide peptidase forms a homodimer that is labeled by an active 
site-directed gamma-secretase inhibitor. J Biol Chem 279(15): 15153-15160. 
  
31.       Miyashita, H., Maruyama, Y., Isshiki, H., Osawa, S., Ogura, T., Mio, K., Sato, C., 
Tomita, T., & Iwatsubo, T. (2011). Three-dimensional structure of the signal peptide 
peptidase. J Biol Chem 286(29): 26188-26197. 
  
32.       Li, X., Dang, S., Yan, C., Gong, X., Wang, J., & Shi, Y. (2013). Structure of a 
presenilin family intramembrane aspartate protease. Nature 493(7430): 56-61. 
  
33.       Voss, M., Schroder, B., & Fluhrer, R. (2013). Mechanism, specificity and 
physiology of signal peptide peptidase (SPP) and SPP-like proteases. BBA 1828: 2828-
2839. 
  
34.       McLauchlan, J., Lemberg, M. K. Hope, G., & Martoglio, B. (2002). 
Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid 
droplets. EMBO 21(15): 3980-3988. 
  
35.       Okamoto, K., Moriishi, K., Miyamura, T., & Matsuura, Y. (2004). Intramembrane 




36.       Ait-Goughoulte, M., Hourioux, C., Patient, R., Trassard, S., Brand, D., & 
Roingeard, P. (2006). Core protein cleavage by signal peptide peptidase is required for 
hepatitis C virus-like particle assembly. J Gen Virol 87(Pt 4): 855-860. 
  
37.       Targett-Adams, P., Schaller, T., Hope, G., Lanford, R. E., Lemon, S. M., Martin, 
A., & McLauchlan, J. (2006). Signal peptide peptidase cleavage of GB virus B core 
protein is required for productive infection in vivo. J Biol Chem 281(39): 29221-29227. 
  
38.       Crawshaw, S. G., Martoglio, B., Meacock, S.L., & High, S. (2004). A 
misassembled transmembrane domain of a polytopic protein associates with signal 
peptide peptidase. Biochem J 384(Pt 1): 9-17. 
  
39.       Schrul, B., Kapp, K., Sinning, I., & Dobberstein, B. (2010). Signal peptide 
peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct 
oligomeric complexes. Biochem J 427(3): 523-534. 
  
40.       Lemberg, M. K., Bland, F. A., Weihofen, A., Braud, V. M., & Martoglio, B. 
(2001). Intramembrane proteolysis of signal peptides: an essential step in the generation 
of HLA-E epitopes. J Immunol 167(11): 6441-6446. 
  
41.       Martoglio, B., Graf, R., & Dobberstein, B. (1997). Signal peptide fragments of 
preprolactin and HIV p-gp160 with calmodulin. EMBO 16(22): 6636-6645. 
  
42.       Weihofen, A., Lemberg, M. K., Ploegh, H. L., Bogyo, M., & Martoglio, B. 
(2000). Release of signal peptide fragments into the cytosol requires cleavage in the 
transmembrane region by a protease activity that is specifically blocked by a novel 
cysteine protease inhibitor. J Biol Chem 275(40): 30951-30956. 
  
43.       Laudon, H., Hansson, E. M., Melén, K., Bergman, A., Farmery, M. R., Winblad, 
B., Lendahl, U., von Heijne, G., & Näslund, J. (2005). A nine-transmembrane domain 
topology for presenilin 1. J Biol Chem 280(42): 35352-35360. 
  
44.       Edbauer, D., Winkler, E., Regula, J. T., Pesold, B., Steiner, H., & Haass, C. 
(2003). Reconstitution of gamma-secretase activity. Nat Cell Biol 5(5): 486-488. 
  
45.       Harris, J. R. (1999). Negative staining of thinly spread biological particulates. 
Methods Mol Biol 117: 13-30. 
  
  
46.       Beebe, E. T., Makino, S., Nozawa, A., Matsubara, Y., Frederick, R.O., Primm, J. 
G., Goren, M. A., & Fox, B. G. (2011). Robotic large-scale application of wheat cell-free 
translation to structural studies including membrane proteins. N Biotechnol 28(3): 239-
249. 
  
47.       Gipson, B., Zeng, X., Zhang, Z. Y., & Stahlberg, H. (2007). 2dx--user-friendly 
image processing for 2D crystals. J Struct Biol 157(1): 64-72. 
 54 
  
48.      Abeyrathne, P. D., Arheit, M., Kebbel, F., Castano-Diez, D., Goldie, K. N., 
Chami, M., & Stahlberg, H. (2012). Analysis of 2-D Crystals of Membrane Proteins by 
Electron Microscopy. Comprehensive Biophysics 1, 277-310  
49.      Schmidt-Krey, I., Kanaoka, Y., Mills, D. J., Irikura, D., Haase, W., Lam, B. K., 
Austen, K. F., & Kühlbrandt, W. (2004). Human leukotriene C(4) synthase at 4.5 A 
resolution in projection. Structure 12(11): 2009-2014. 
  
50.       Schmidt-Krey, I., Haase, W., Mutucumarana, V., Stafford, D. W., & Kühlbrandt, 
W. (2007b). Two-dimensional crystallization of human vitamin K-dependent gamma-
glutamyl carboxylase. J Struct Biol 157(2): 437-442. 
  
51.       Schmidt-Krey, I., Lundqvist, G., Morgenstern, R., & Hebert, H. (1998). 
Parameters for the two-dimensional crystallization of the membrane protein microsomal 
glutathione transferase. J Struct Biol 123(2): 87-96. 
  
52.       sbkb.org. (April 27, 2012). Structural Biology Center: Protocol ID: LP.909 (Oct. 
22, 2012). from http://sbkb.org/tt/protocol?ttid=TEMIMPS-
GO.15205&lab=TEMIMPS&trialid=2&protocolid=LP.909 
  
53.       Vink, M., Derr, K., Love, J., Stokes, D. L., & Ubarretxena-Belandia, I. (2007). A 
high-throughput strategy to screen 2D crystallization trials of membrane proteins. J Struct 
Biol 160(3): 295-304. 
  
54.       Kebbel, F., Kurz, M., Grütter, M. G., & Stahlberg, H. (2012). Projection structure 
of the secondary citrate/sodium symporter CitS at 6 A resolution by electron 
crystallography. J Mol Biol 418(1-2): 117-126. 
  
55.       Kebbel, F., Kurz, M., Arheit, M., Grütter, M. G., & Stahlberg, H. (2013). 
Structure and substrate-induced conformational changes of the secondary citrate/sodium 
symporter CitS revealed by electron crystallography. Structure 21(7): 1243-1250. 
 
 
 
 
  
 
